7 February 2024
7 February 2024 This release contains inside information 2024 INTERIM RESULTS for the six months ended 2 December 2023 Jonathan Myers, Chief Executive Officer,…
7 FEBRUARY 2024 RECOMMENDED ALL-SHARE OFFER FOR THE COMBINATION of BARRATT DEVELOPMENTS PLC (“Barratt”) and REDROW PLC (“Redrow”) Summary · The boards of…
7 February 2024 BARRATT DEVELOPMENTS PLC Half year results for the six month period ended 31 December 2023 Solid operating performance in an uncertain…
6 February 2024
2023 : A year of delivery Financial summary Fourth Third Fourth quarter quarter quarter Year Year $…
· Application supported by positive results of a phase III trial showing immune response and acceptable tolerability profile in this population · Adults aged 50 and…
GSK’s regulatory application for Shingrix for the prevention of shingles in at-risk adults aged 18 and over accepted for review by China National Medical Products Administration…
DREAMM-7 phase III trial shows Blenrep combination nearly tripled median progression-free survival versus standard of care combination in patients with relapsed/refractory multiple myeloma · 59% reduction in…
5 February 2024
5 February 2024 Sustained revenue growth in Europe & Africa Margherita Della Valle, Vodafone Group Chief Executive, commented: “We maintained good service…